Lyn — Proto Oncogene Tyrosine Protein Kinase Lyn is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Lyn (Proto-Oncogene Tyrosine-Protein Kinase Lyn) is a Src family non-receptor tyrosine kinase with unique dual roles in both the immune system and nervous system. It is a 56 kDa protein encoded by the LYN gene on chromosome 8q13.1. Unlike other SFKs, Lyn is primarily expressed in hematopoietic cells (B lymphocytes, myeloid cells, mast cells) and in microglia, where it serves as both a positive and negative regulator of immune signaling. In the nervous system, Lyn regulates microglial activation, neuroinflammation, and synaptic plasticity (Xu et al., 2012).
|
|
| Protein Name |
Proto-Oncogene Tyrosine-Protein Kinase Lyn |
| Gene |
LYN |
| UniProt ID |
P07948 |
| Molecular Weight |
56 kDa |
| Subcellular Localization |
Plasma membrane, Cytoplasm, Endosomes |
| Protein Family |
Src family non-receptor tyrosine kinases |
Lyn shares the canonical Src family kinase architecture with some unique features:
- N-terminal myristoylation and palmitoylation: Dual lipid modification for membrane targeting, similar to Fyn
- Unique domain (residues 1-65): Lyn-specific sequences that determine substrate specificity; contains binding sites for immune receptors
- SH3 domain (residues 68-125): Binds proline-rich sequences; autoinhibitory function
- SH2 domain (residues 130-205): Phosphotyrosine binding; regulatory interactions
- Catalytic kinase domain (residues 240-490): ATP binding and phosphotransferase activity
- C-terminal tail: Tyr508 (human) phosphorylation by CSK maintains autoinhibition
Lyn exists as two alternatively spliced isoforms: LynA (56 kDa, full-length) and LynB (53 kDa, lacking 21 amino acids in the unique domain), with potentially different signaling properties (Corey et al., 1998).
Lyn is the predominant SFK in B cells and myeloid cells:
- B cell receptor (BCR) signaling: Phosphorylates ITAM motifs on Ig-α/Ig-β, initiating BCR signaling cascades
- Negative regulation: Phosphorylates ITIM motifs on inhibitory receptors (CD22, FcγRIIB), recruiting SHIP-1 phosphatase to dampen signaling
- Mast cell degranulation: Regulates FcεRI signaling and histamine release
- Dendritic cell function: Modulates antigen presentation and cytokine production
In the central nervous system, Lyn is highly expressed in microglia:
- Toll-like receptor (TLR) signaling: Phosphorylates TLR4 and adaptor proteins, modulating inflammatory responses to bacterial LPS
- TREM2 signaling: May modulate TREM2-DAP12 signaling in microglia, affecting phagocytosis and inflammatory phenotypes
- Fc receptor signaling: Regulates microglial response to antibody-opsonized material
- Cytokine production: Controls production of TNF-α, IL-6, and other inflammatory mediators
Lower levels of Lyn are found in neurons where it modulates:
- NMDA receptor function: Can phosphorylate NMDA receptor subunits, similar to Fyn
- GABAergic transmission: Modulates GABA receptor function in some contexts
- Synaptic plasticity: Contributes to long-term potentiation and depression
Lyn's role in neuroinflammation links it to multiple neurodegenerative conditions:
- Microglial activation: Lyn mediates inflammatory signaling in activated microglia surrounding amyloid plaques
- Aβ-induced inflammation: Aβ activates microglial Lyn, contributing to IL-1β and TNF-α production
- Complement receptor signaling: Lyn modulates microglial phagocytosis of complement-opsonized synapses
- Negative regulation paradox: Lyn also has inhibitory functions; Lyn deficiency can worsen inflammation in some models
- Microglial neuroinflammation: Lyn contributes to inflammatory responses in dopaminergic neuron degeneration
- α-synuclein effects: Extracellular α-synuclein activates microglial Lyn, promoting inflammatory cytokine release
- LRRK2 interactions: Potential crosstalk between LRRK2 and Lyn pathways in PD
- Demyelinating inflammation: Lyn mediates microglial activation in MS lesions
- Regulatory functions: May also have protective anti-inflammatory roles through ITIM phosphorylation
Lyn polymorphisms and dysregulation are associated with:
- Systemic lupus erythematosus (SLE): Lyn-deficient mice develop lupus-like autoimmunity; human LYN variants linked to SLE risk
- Rheumatoid arthritis: Lyn contributes to inflammatory signaling in synovial tissue
- Inflammatory bowel disease: Lyn modulates intestinal immune responses
- Leukemia: Constitutively active Lyn in some B-cell malignancies
- Glioma: Lyn expression in glioblastoma contributes to invasion and proliferation
Several multi-kinase inhibitors affect Lyn:
- Dasatinib: Potent Lyn inhibitor (IC50 ~0.5 nM); approved for leukemia; limited brain penetration limits neurodegeneration applications
- Bosutinib: Inhibits Lyn among other kinases
- Saracatinib: Inhibits Lyn along with Fyn and Src; better brain penetration
Targeting Lyn for neurodegeneration remains largely experimental:
- Microglia-specific inhibition: Preventing neuroinflammation while preserving protective immune functions
- Negative regulation enhancement: Boosting Lyn's inhibitory phosphorylation functions
- Isoform-selective targeting: Different effects of LynA vs LynB may be therapeutically relevant
- Dual functions: Lyn's both activating and inhibitory roles complicate therapeutic targeting
- Peripheral immune effects: Systemic Lyn inhibition may impair normal immune function
- Blood-brain barrier: Need for CNS-penetrant compounds for neurodegeneration
-
Xu Y, Harder KW, Huntington ND, Hibbs ML. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity. 2012;36(4):515-24. doi:10.1016/j.immuni.2012.04.004
-
Corey SJ, Anderson SM. Src-related tyrosine protein kinases in hematopoiesis. Blood. 1999;93(1):1-14. PMID:9864146
-
Hibbs ML, Harder KW, Armes J, et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med. 2002;196(12):1593-604. doi:10.1084/jem.20020715
The study of Lyn — Proto Oncogene Tyrosine Protein Kinase Lyn has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.